https://www.frontiersin.org/articles/10.3389/fped.2021.631329/full?utm_source=twitter&utm_medium=social&utm_content=i4&utm_campaign=imp_impart-_02-23_fped_en_n-fped-eur-nam-jpn-anz “the characterization of #interferonopathy molecular pathogenetic mechanisms is allowing important steps forward in other #ImmuneDysregulation diseases, such as #SystemicLupusErythematosus and inflammatory #myositis, implementing the opportunity of a more effective target therapy.”